DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 200 filers reported holding DENALI THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 9.23 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $1,021,501 | -72.7% | 44,336 | -67.0% | 0.00% | -75.0% |
| Q4 2022 | $3,738,415 | +47.5% | 134,427 | +56.1% | 0.00% | +33.3% |
| Q2 2022 | $2,534,000 | +1160.7% | 86,113 | +1278.2% | 0.00% | – |
| Q1 2022 | $201,000 | -37.8% | 6,248 | -13.7% | 0.00% | – |
| Q4 2021 | $323,000 | -85.9% | 7,236 | -84.1% | 0.00% | -100.0% |
| Q3 2021 | $2,291,000 | -65.1% | 45,413 | -45.7% | 0.00% | -66.7% |
| Q2 2021 | $6,557,000 | -44.3% | 83,585 | -59.5% | 0.01% | -45.5% |
| Q1 2021 | $11,772,000 | +77.1% | 206,162 | +159.8% | 0.01% | +83.3% |
| Q4 2020 | $6,647,000 | +27.9% | 79,360 | -45.3% | 0.01% | +20.0% |
| Q3 2020 | $5,196,000 | +144.7% | 145,018 | +41.8% | 0.01% | +66.7% |
| Q2 2019 | $2,123,000 | – | 102,274 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 19,462,500 | $339,037,000 | 35.95% |
| Euclidean Capital LLC | 323,749 | $27,117,000 | 5.74% |
| Flagship Pioneering Inc. | 2,730,263 | $228,687,000 | 4.16% |
| Casdin Capital, LLC | 1,310,000 | $109,726,000 | 3.25% |
| A.R.T. Advisors, LLC | 6,173 | $517,000 | 2.39% |
| MARK ASSET MANAGEMENT LP | 172,040 | $14,410,000 | 1.73% |
| Temasek Holdings (Private) Ltd | 4,410,457 | $369,420,000 | 1.59% |
| Integral Health Asset Management, LLC | 57,500 | $4,816,000 | 1.43% |
| GILDER GAGNON HOWE & CO LLC | 3,219,843 | $269,694,000 | 1.34% |
| IRONWOOD INVESTMENT MANAGEMENT LLC | 19,365 | $1,622,000 | 0.95% |